β1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6692-6700

  Goel, Hira Lal ^a   Breen, Michael ^a   Zhang, Jianzhong ^a   Das, Ishita ^a   Aznavoorian Cheshire, Sadie ^a   Greenberg, Norman M ^b   Elgavish, Ada ^c   Languino, Lucia R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BETA1A INTEGRIN; BETA1C INTEGRIN; GROWTH FACTOR; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; GAB1 PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CELL SURFACE; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL ADHESION; CELL GROWTH; DOWN REGULATION; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TRANSGENIC MOUSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANIMALS; ANTIGENS, CD29; CELL ADHESION; CELL GROWTH PROCESSES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 23044482717     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4315     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Nicholson B, Theodorescu D. Molecular therapeutics in prostate cancer. Histol Histopathol 2003;18: 275-98.
3. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000;55:323-7.
4. Boudreau N, Myers C, Bissell MJ. From laminin to lamin: regulation of tissue-specific gene expression by the ECM. Trends Cell Biol 1995;5:1-4.
5. Quaranta V, Plopper GE. Integrins and laminins in tissue remodeling. Kidney Int 1997;51:1441-6.
6. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999;76:1-20.
7. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. Cancer Metastasis Rev 2003; 20:321-31.
8. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003;22: 6524-36.
9. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Coordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997;33:263-71.
10. 6-integrins in the normal and neoplastic prostate. Am J Pathol 1994;145:167-74.
11. Hemler ME. Integrin associated proteins. Curr Opin Cell Biol 1998;10:578-85.
12. Fornaro M, Languino LR. Alternatively spliced variants: a new view of the integrin cytoplasmic domain. Matrix Biol 1997;16:185-93.
13. 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Am J Pathol 1996;149:765-73.
14. 1C inhibits prostate epithelial cell proliferation. Am J Pathol 1998;153:1079-87.
15. 1C integrin in prostatic adenocareinoma. J Clin Invest 1999; 103:321-9.
16. 1C integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size. Am J Pathol 2000;156:169-74.
17. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ Res 2001;89:1104-10.
18. Baserga R. The IGF-1 receptor in cancer research. Exp Cell Res 2003;253:1-6.
19. Neudauer CL, McCarthy JB. Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation. Exp Cell Res 2003;286:128-37.
20. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V. Insulin-like growth factor (IGF)-1, IGF-II and IGF type 1 receptor (IGFR-1) expression in prostatic cancer. Anticancer Res 1996;23:3825-35.
21. Tennant MK, Thrasher JB, Twomey PA Drivdahl RH, Birnbaum RS, Plymate SR. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-82.
22. Chott A, Sun Z, Morganstern D, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271-9.
23. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999; 59:2203-9.
24. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-1R). Cancer Res 2001;61:6276-80.
25. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
26. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 1996;379:560-4.
27. Winnay JN, Bruning JC, Burks DJ, Kahn CR. Gab-1-mediated IGF-1 signaling in IRS-1-deficient 3T3 fibroblasts. J Biol Chem 2000;275:10545-50.
28. Gu H, Neel BG. The "Gab" in signal transduction. Trends Cell Biol 2003;13:122-30.
29. 1 integrins. J Cell Biol 1995; 166:407-18.
30. Kameda H, Risinger JI, Han BB, et al. Expression of Gab1 lacking the pleckstrin homology domain is associated with neoplastic progression. Mol Cell Biol 2001;21:6895-905.
31. 1C integrin cytoplasmic domain variant. Exp Mol Pathol 2001;70:275-80.
32. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82.
33. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
34. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91.
35. Folkvord JM, Viders D, Coleman-Smith A, Clark RA. Optimization of immunohistochemical techniques to detect extracellular matrix proteins in fixed skin specimens. J Histochem Cytochem 1989;37:105-13.
36. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305.
37. Wennerberg K, Lohikangas L, Gullberg D, Pfaff M, Johansson S, Fassler R. β1 integrin-dependent and -independent polymerization of fibronectin. J Cell Biol 1996;132:227-38.
38. Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, Languino LR. αvβ3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 2003;161:817-26.
39. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
40. Rubini M, Hongo A, D'Ambrosio C, Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 1997;230:284-92.
41. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54:133-7.
42. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.
43. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14:3604-12.
44. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993;90:11217-21.
45. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000;19: 5606-13.
46. 1 integrin is essential for teratoma growth and angiogenesis. J Cell Biol 1997;139:265-78.
47. 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004; 6:159-70.
48. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R. Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene 2001;20:490-500.
49. Vuori K, Ruoslahti E. Association of insulin receptor substrate-1 with integrins. Science (Wash DC) 1994;266: 1576-9.
50. Ling Y, Maile LA, Badley Clarke J, Clemmons DR. DOK1 mediates SHP-2 binding to the αVβ3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem 2005;280:3151-8.